CA2967112C - Quinoline carboxamides for use in the treatment of leukemia - Google Patents
Quinoline carboxamides for use in the treatment of leukemia Download PDFInfo
- Publication number
- CA2967112C CA2967112C CA2967112A CA2967112A CA2967112C CA 2967112 C CA2967112 C CA 2967112C CA 2967112 A CA2967112 A CA 2967112A CA 2967112 A CA2967112 A CA 2967112A CA 2967112 C CA2967112 C CA 2967112C
- Authority
- CA
- Canada
- Prior art keywords
- leukemia
- pharmaceutically acceptable
- compound
- acceptable salt
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14193776.3 | 2014-11-19 | ||
| EP14193776 | 2014-11-19 | ||
| PCT/EP2015/075769 WO2016078921A1 (en) | 2014-11-19 | 2015-11-05 | Quinoline carboxamides for use in the treatment of leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2967112A1 CA2967112A1 (en) | 2016-05-26 |
| CA2967112C true CA2967112C (en) | 2023-05-16 |
Family
ID=51951635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2967112A Active CA2967112C (en) | 2014-11-19 | 2015-11-05 | Quinoline carboxamides for use in the treatment of leukemia |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10300053B2 (enExample) |
| EP (1) | EP3180005B1 (enExample) |
| JP (1) | JP6715833B2 (enExample) |
| KR (1) | KR102525805B1 (enExample) |
| CN (1) | CN107072989B (enExample) |
| AU (1) | AU2015348778B2 (enExample) |
| BR (1) | BR112017009854B1 (enExample) |
| CA (1) | CA2967112C (enExample) |
| EA (1) | EA031643B1 (enExample) |
| ES (1) | ES2663836T3 (enExample) |
| IL (1) | IL252174B (enExample) |
| MX (1) | MX379401B (enExample) |
| NZ (1) | NZ732704A (enExample) |
| PL (1) | PL3180005T3 (enExample) |
| WO (1) | WO2016078921A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3168070A1 (en) | 2020-03-03 | 2021-09-10 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
| AU2021313388A1 (en) | 2020-07-23 | 2023-01-19 | Erasmus University Medical Center Rotterdam (Erasmus Mc) | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
| PL4277628T3 (pl) * | 2021-01-18 | 2026-02-09 | Active Biotech Ab | Taskwinimod lub jego farmaceutycznie dopuszczalna sól do stosowania w leczeniu zespołu mielodysplastycznego |
| CN116887844A (zh) * | 2021-01-18 | 2023-10-13 | 活跃生物技术有限公司 | 用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐 |
| JP2024520307A (ja) | 2021-05-25 | 2024-05-24 | アクティブ バイオテック エイビー | 複数のタスキニモド粒子およびその使用 |
| JP2024524158A (ja) | 2021-07-02 | 2024-07-05 | アクティブ バイオテック エイビー | タスキニモドを含有する医薬製品および前記製品の純度を評価する方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| EP2590949B1 (en) | 2010-07-09 | 2015-11-25 | Active Biotech AB | Method for manufacturing of quinoline-3-carboxamides |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| WO2015095833A1 (en) | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Treatment of hematologic cancers |
-
2015
- 2015-11-05 ES ES15790143.0T patent/ES2663836T3/es active Active
- 2015-11-05 MX MX2017006110A patent/MX379401B/es unknown
- 2015-11-05 EP EP15790143.0A patent/EP3180005B1/en active Active
- 2015-11-05 EA EA201791099A patent/EA031643B1/ru not_active IP Right Cessation
- 2015-11-05 CN CN201580062750.4A patent/CN107072989B/zh active Active
- 2015-11-05 AU AU2015348778A patent/AU2015348778B2/en active Active
- 2015-11-05 US US15/525,086 patent/US10300053B2/en active Active
- 2015-11-05 PL PL15790143T patent/PL3180005T3/pl unknown
- 2015-11-05 JP JP2017525360A patent/JP6715833B2/ja active Active
- 2015-11-05 CA CA2967112A patent/CA2967112C/en active Active
- 2015-11-05 NZ NZ732704A patent/NZ732704A/en unknown
- 2015-11-05 WO PCT/EP2015/075769 patent/WO2016078921A1/en not_active Ceased
- 2015-11-05 BR BR112017009854-7A patent/BR112017009854B1/pt active IP Right Grant
- 2015-11-05 KR KR1020177015989A patent/KR102525805B1/ko active Active
-
2017
- 2017-05-09 IL IL252174A patent/IL252174B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EA201791099A1 (ru) | 2017-10-31 |
| NZ732704A (en) | 2022-01-28 |
| KR20170083121A (ko) | 2017-07-17 |
| MX2017006110A (es) | 2017-07-27 |
| IL252174B (en) | 2021-02-28 |
| AU2015348778A1 (en) | 2017-06-29 |
| BR112017009854B1 (pt) | 2022-08-23 |
| EP3180005A1 (en) | 2017-06-21 |
| KR102525805B1 (ko) | 2023-04-25 |
| PL3180005T3 (pl) | 2018-06-29 |
| CN107072989B (zh) | 2020-07-03 |
| ES2663836T3 (es) | 2018-04-17 |
| BR112017009854A2 (pt) | 2018-01-16 |
| MX379401B (es) | 2025-03-11 |
| CN107072989A (zh) | 2017-08-18 |
| US10300053B2 (en) | 2019-05-28 |
| CA2967112A1 (en) | 2016-05-26 |
| JP2017534652A (ja) | 2017-11-24 |
| JP6715833B2 (ja) | 2020-07-01 |
| WO2016078921A1 (en) | 2016-05-26 |
| IL252174A0 (en) | 2017-07-31 |
| EP3180005B1 (en) | 2017-12-27 |
| EA031643B1 (ru) | 2019-01-31 |
| AU2015348778B2 (en) | 2020-12-24 |
| US20170319568A1 (en) | 2017-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10300053B2 (en) | Quinoline carboxamides for use in the treatment of leukemia | |
| JP7223998B2 (ja) | Ａｘｌ阻害剤を有効成分として含む固形がん治療剤 | |
| US10314836B2 (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| CN104436194B (zh) | 具有协同增效作用的抗癌组合物 | |
| CN117064897A (zh) | 用于治疗血液病的化合物和组合物 | |
| TW202019409A (zh) | Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或bcl-2抑制劑與chop聯合用藥的協同抗腫瘤作用 | |
| JP2017534652A5 (enExample) | ||
| HK1237658B (en) | Quinoline carboxamides for use in the treatment of leukemia | |
| HK1237658A1 (en) | Quinoline carboxamides for use in the treatment of leukemia | |
| HK1226643A1 (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| HK1226643B (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| CN112535686B (zh) | 激酶抑制剂的新用途 | |
| BR112017004947B1 (pt) | Uso de um composto ou sal farmaceuticamente aceitável | |
| AU2024306742A1 (en) | Quinoline carboxamides for use in the treatment of mpn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201015 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241028 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241028 |